Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma. Local targets link to admitted publications; unresolved targets remain external evidence.
Multiple myeloma
10.1038/nrdp.2017.46 · 2017 · External reference
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
10.1016/s1470-2045(20)30525-8 · 2020 · External reference
Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t (11; 14)
10.1200/jco.21.00443 · 2021 · External reference
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
10.1182/bloodadvances.2020004146 · 2021 · External reference
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
10.1182/blood.2020007899 · 2021 · External reference
Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models
10.1158/1535-7163.mct-15-0730 · 2016 · External reference
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
10.1016/j.ccr.2006.08.027 · 2006 · External reference
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1–expressing myeloma cells
10.1182/blood-2011-01-327197 · 2011 · External reference
Myeloid cell factor–1 is a critical survival factor for multiple myeloma
10.1182/blood.v99.6.1885 · 2002 · External reference
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma
10.1158/0008-5472.can-06-4322 · 2007 · External reference
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
10.1182/blood-2017-06-788323 · 2017 · External reference
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
10.1182/blood-2017-06-788786 · 2017 · External reference
Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction
10.1101/gad.215855.113 · 2013 · External reference
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma
10.1038/s41375-018-0374-8 · 2019 · External reference
Venetoclax ex vivo functional profiling predicts improved progression-free survival
10.1038/s41408-022-00710-9 · 2022 · External reference
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
10.1038/leu.2013.216 · 2014 · External reference
Understanding MCL1: from cellular function and regulation to pharmacological inhibition
10.1111/febs.16136 · 2022 · External reference
Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure
10.1101/gad.215871.113 · 2013 · External reference
CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263
10.1038/s41419-019-1831-7 · 2019 · External reference
CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo
10.1080/10428194.2023.2169045 · 2023 · External reference
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
2017 · External reference
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma
2023 · External reference
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
10.1126/sciadv.abg9551 · 2021 · External reference
BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models
10.1016/j.ccell.2019.04.005 · 2019 · External reference
The covalent CDK7 inhibitor THZ1 potently induces apoptosis in multiple myeloma cells in vitro and in vivo
10.1158/1078-0432.ccr-18-3788 · 2019 · External reference
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
10.1038/nature13393 · 2014 · External reference
Searching for drug synergy in complex dose–response landscapes using an interaction potency model
10.1016/j.csbj.2015.09.001 · 2015 · External reference
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
10.1038/leu.2017.179 · 2018 · External reference
Mcl-1 is essential for the survival of plasma cells
10.1038/ni.2527 · 2013 · External reference
Chromosome 1q21 abnormalities in multiple myeloma
10.1038/s41408-021-00474-8 · 2021 · External reference
MCL-1 inhibition by selective BH3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes
10.1016/j.isci.2020.101015 · 2020 · External reference
Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4
10.1182/blood-2012-03-415984 · 2012 · External reference
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies
10.1038/s41375-019-0652-0 · 2020 · External reference
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
10.1038/nature19830 · 2016 · External reference
Na,K-ATPase subunit heterogeneity as a mechanism for tissue-specific ion regulation
10.1016/j.semnephrol.2005.03.004 · 2005 · External reference
FKBPL: a marker of good prognosis in breast cancer
10.18632/oncotarget.3528 · 2015 · External reference
